A randomised, placebo-controlled trial of Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia in chronic kidney disease [ 2011 - 2015 ]

Research Grant

Researchers: Prof David Johnson (Principal investigator) ,  A/Pr Eugenia Pedagogos ,  Prof Paolo Ferrari ,  Prof Philip Clarke ,  Prof Robert Fassett
View all 6 related researchers

Brief description Anaemia in chronic kidney disease (CKD) is linked to poor health outcomes, increased death rates and high health care costs. Drugs that stimulate red blood cell production are routinely used to treat CKD patients with anaemia, however some patients do not respond to these drugs. The HERO trial is a clinical trial designed to test the safety, effectiveness and cost benefits of a drug Oxypentifylline, in treating CKD patients with anaemia that is unresponsive to red blood cell stimulating treatments.

Funding Amount $AUD 345,189.49

Funding Scheme Project Grants

Notes Standard Project Grant